Veru (NASDAQ:VERU) Earns "Sell (E+)" Rating from Weiss Ratings

Key Points

• Weiss Ratings has reaffirmed its "sell (E+)" rating for Veru (NASDAQ:VERU) amidst ongoing concerns about the company's performance.
• Raymond James Financial has reduced its price target for Veru from $30.00 to $20.00, maintaining an "outperform" rating, while analysts have a consensus target price of $33.33 for the stock.
• Veru reported quarterly earnings exceeding estimates, with an EPS of ($0.50), though analysts predict a projected earnings decline for the current fiscal year.

Veru (NASDAQ:VERU - Get Free Report)'s stock had its "sell (e+)" rating reaffirmed by research analysts at Weiss Ratings in a research note issued to investors on Wednesday,Weiss Ratings reports.

Separately, Raymond James Financial dropped their price objective on Veru from $30.00 to $20.00 and set an "outperform" rating for the company in a report on Wednesday, August 13th. Three analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. According to MarketBeat, the stock currently has an average rating of "Moderate Buy" and a consensus target price of $33.33.

Veru Stock Performance

NASDAQ:VERU traded up $0.06 during trading on Wednesday, reaching $4.41. The company's stock had a trading volume of 219,305 shares, compared to its average volume of 161,655. The firm has a market cap of $64.65 million, a price-to-earnings ratio of -2.00 and a beta of -0.75. The firm has a 50 day moving average of $3.67 and a 200-day moving average of $4.94. Veru has a 12 month low of $2.64 and a 12 month high of $14.20.

Veru (NASDAQ:VERU - Get Free Report) last issued its quarterly earnings data on Tuesday, August 12th. The company reported ($0.50) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.55) by $0.05. Equities research analysts forecast that Veru will post -0.22 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently bought and sold shares of VERU. Catalyst Funds Management Pty Ltd purchased a new position in shares of Veru during the 2nd quarter valued at about $36,000. Allworth Financial LP purchased a new stake in Veru during the 2nd quarter worth approximately $45,000. XTX Topco Ltd purchased a new stake in Veru during the 2nd quarter worth approximately $49,000. Weaver Consulting Group increased its stake in Veru by 27.4% during the 1st quarter. Weaver Consulting Group now owns 88,838 shares of the company's stock worth $44,000 after buying an additional 19,133 shares in the last quarter. Finally, Sender Co & Partners Inc. purchased a new stake in shares of Veru in the first quarter valued at approximately $64,000. Institutional investors own 47.16% of the company's stock.

Veru Company Profile

Veru Inc, a late clinical stage biopharmaceutical company, focuses on developing medicines for treatment of metabolic diseases, oncology, and acute respiratory distress syndrome (ARDS). Its marketed products comprise FC2 female condom for the dual protection against unplanned pregnancy and the transmission of sexually transmitted infections.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.